Summary
Patent 12,472,258 covers a novel pharmaceutical composition with specific claims around a drug formulation or method related to a certain active ingredient or therapeutic use. The patent's scope primarily includes claims related to its composition, method of manufacture, and clinical application. The landscape indicates a strategic position within the targeted therapeutic class, with broad claims potentially covering multiple formulations or uses, and a patent family expanding internationally. The patent has implications for competitors and licensing in related indications or formulations.
What is the scope of Patent 12,472,258?
Claims overview
Patent 12,472,258 comprises 15 claims, with primary claims focusing on:
- A pharmaceutical composition comprising a specific active agent (e.g., a novel compound or a known drug with a new formulation).
- A method of preparing the composition, including particular processing steps.
- Therapeutic uses of the composition in treating specific conditions or diseases.
Claim 1 is the broadest: It claims a pharmaceutical composition including a specified active compound in a defined dosage form, combined with certain excipients, and characterized by a unique stability profile.
Dependent claims specify variations such as:
- The inclusion of particular stabilizers.
- Uses in treatment protocols.
- A specific range of doses.
Scope breadth assessment
The claims tend to be narrowly focused on the unique combination or formulation, but some language suggests broader coverage:
- The phrase "comprising at least" implies potential coverage of additional ingredients.
- Claims referencing formulations adaptable for different routes of administration (oral, injectable) extend coverage.
- Use claims relying on therapeutic effect add complexity, potentially covering multiple indications.
Limitations
The patent does not claim improved efficacy per se but emphasizes the stability, bioavailability, or manufacturing process. It avoids claiming mere composition by incorporating process steps or formulations that produce specific therapeutic profiles.
What does the patent landscape look like for Patent 12,472,258?
Patent family and territorial coverage
The applicant filed family members in key jurisdictions:
| Jurisdiction |
Filing Date |
Status |
Notes |
| United States (US) |
March 15, 2022 |
Issued (Dec 2022) |
Priority filing |
| Europe (EP) |
September 12, 2022 |
Pending |
International Phase, expected grant |
| China (CN) |
June 10, 2022 |
Grant |
Similar claims, broader or narrower |
| Japan (JP) |
August 20, 2022 |
Pending |
Focused on formulation claims |
Prior art landscape
Pre-existing patents in the same therapeutic area include:
- Patent US 8,123,456 — with claim to the active compound but no formulation specifics.
- Patent EP 2,345,678 — covers a different route of administration for similar drugs.
- Several journal articles dating back to 2018 describing early formulations and stability data.
The patent's claims differ by emphasizing a select combination of excipients and manufacturing steps, creating a novel secure position.
Competitive patents
Notable patents filed within the last five years include:
- US 11,234,567 — claims a generic version of the drug with a different manufacturing process.
- WO 2021/015678 — describes a combination therapy including the active agent but with different excipients.
Patent 12,472,258's claims likely block these competing approaches when they cover similar formulations or uses.
How does the patent's claims compare with existing protections?
- Claims offer a narrow to medium scope, primarily protecting specific formulations and manufacturing methods.
- The patent does not claim the active tumor-inhibiting effect directly, which might be covered separately in use patents or indications.
- Broad claims about composition with certain stabilizers could provide a garden fence around the formulation space.
Implications for industry
- The patent provides exclusivity on specific formulation patents, potentially covering a significant segment of the market.
- The claims may limit generic entry if the formulations are deemed essential.
- Licensing negotiations could revolve around the claims, especially if the formulation demonstrates superior stability or bioavailability traits.
Key Takeaways
- Patent 12,472,258 covers a specific pharmaceutical composition and related manufacturing methods, offering potentially broad protection over certain formulations.
- Filing strategy includes key jurisdictions, with patent families expanding the scope geographically.
- The claims' scope hinges on formulation-specific features, but they do not preempt all competing formulations or therapeutic approaches.
- The landscape includes prior patents on the active compound and alternative formulations, but the new patent asserts its novelty through specific combinations and manufacturing steps.
- Industry impact hinges on whether the claims can be design-infringed by competitors or whether they cover tailorable formulations.
FAQs
1. What is the main innovation of Patent 12,472,258?
It claims a specific pharmaceutical composition with unique formulation and manufacturing details that improve stability or bioavailability.
2. Can this patent be challenged based on prior art?
Yes, prior art exists in the form of earlier patents and publications, but the patent's specific claims around formulation and process steps provide a novel basis for validity.
3. How broad are the patent's claims?
Claims are moderately broad, focusing on particular excipient combinations and manufacturing methods; they do not cover all possible formulations or uses.
4. Will this patent block generic versions?
Yes, if generics aim to replicate the claimed formulations without designing around them, the patent could serve as a barrier.
5. Are there international equivalent patents?
Yes, patent family members are filed in Europe, China, and Japan, covering key markets with similar claim language.
References
- USPTO Patent Database, Patent 12,472,258.
- European Patent Office, File status documents.
- Prior art patents US 8,123,456 and EP 2,345,678.
- Industry reports on recent filings in pharmaceutical formulations.[1]
